** Shares of medical device maker Dexcom DXCM.O fall 6.2% to $73 in extended trade
** Co says it had received a warning letter from the U.S. FDA following inspections of its two key manufacturing facilities
** The warning letter contains observations and identified issues in manufacturing processes and quality management system at DXCM's facilities in San Diego, California and Mesa, Arizona
** Co does not expect a material impact from the letter to its manufacturing capacity or its sales outlook for fiscal year 2025
** DXCM fell 37.3% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.